Caris Life Sciences, Inc. $CAI Shares Bought by TD Asset Management Inc

TD Asset Management Inc raised its stake in Caris Life Sciences, Inc. (NASDAQ:CAI) by 248.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 773,852 shares of the company’s stock after acquiring an additional 551,516 shares during the quarter. TD Asset Management Inc’s holdings in Caris Life Sciences were worth $20,879,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Goldman Sachs Group Inc. lifted its holdings in Caris Life Sciences by 24.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 350,142 shares of the company’s stock valued at $9,447,000 after acquiring an additional 67,933 shares during the period. AXQ Capital LP acquired a new position in Caris Life Sciences in the fourth quarter valued at approximately $329,000. BNP Paribas Financial Markets lifted its holdings in Caris Life Sciences by 57,052.2% in the fourth quarter. BNP Paribas Financial Markets now owns 685,826 shares of the company’s stock valued at $18,504,000 after acquiring an additional 684,626 shares during the period. Norges Bank acquired a new position in Caris Life Sciences in the fourth quarter valued at approximately $2,976,000. Finally, Seven Grand Managers LLC lifted its holdings in Caris Life Sciences by 395.1% in the fourth quarter. Seven Grand Managers LLC now owns 495,095 shares of the company’s stock valued at $13,358,000 after acquiring an additional 395,095 shares during the period.

Caris Life Sciences Price Performance

Shares of CAI stock opened at $16.49 on Monday. The company has a current ratio of 7.05, a quick ratio of 6.52 and a debt-to-equity ratio of 0.64. The firm has a market cap of $4.66 billion and a P/E ratio of -2.17. The stock’s 50 day simple moving average is $17.85. Caris Life Sciences, Inc. has a 1-year low of $14.19 and a 1-year high of $42.50.

Insider Buying and Selling at Caris Life Sciences

In other Caris Life Sciences news, Director Jeff L. Vacirca bought 31,050 shares of Caris Life Sciences stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $16.15 per share, with a total value of $501,457.50. Following the purchase, the director directly owned 49,671 shares in the company, valued at $802,186.65. This represents a 166.75% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 50.00% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on CAI shares. Wall Street Zen downgraded Caris Life Sciences from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. New Street Research began coverage on Caris Life Sciences in a report on Friday, May 8th. They issued a “market perform” rating for the company. BTIG Research reduced their target price on Caris Life Sciences from $38.00 to $32.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Citigroup reduced their target price on Caris Life Sciences from $35.00 to $28.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Finally, Piper Sandler began coverage on Caris Life Sciences in a research note on Friday, April 10th. They set a “neutral” rating and a $21.00 target price for the company. Six equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Caris Life Sciences currently has an average rating of “Hold” and a consensus price target of $27.56.

Caris Life Sciences Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.